FDA Approved: LENVIMA — Supplemental Application (Eisai Inc.)

View source ↗

Summary

FDA approved a supplemental application for LENVIMA (lenvatinib) submitted by Eisai Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Renal Cell Carcinoma
• Unresectable Biliary Tract Cancer
• Unresectable Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

SUPPL AP for LENVIMA (LENVATINIB)